482305-98-6 Usage
Description
(dl)-5-chloro-N-[2-hydroxy-3-[[4-(3-oxo-4-morpholino)phenyl]amino]propyl]-2-thiophenecarboxamide is a complex organic compound with a chemical structure that includes a 5-chloro-thiophene carboxamide backbone, a 3-oxo-4-morpholino phenyl group, and a hydroxy-amino propyl side chain. This molecule is characterized by its potential pharmaceutical applications due to its structural features that may allow for interactions with specific biological targets.
Uses
Used in Pharmaceutical Industry:
(dl)-5-chloro-N-[2-hydroxy-3-[[4-(3-oxo-4-morpholino)phenyl]amino]propyl]-2-thiophenecarboxamide is used as an impurity in the development and manufacturing process of Rivaroxaban (R538000), a novel antithrombotic agent. Rivaroxaban is a highly potent and selective, direct FXa inhibitor, which plays a crucial role in the treatment and prevention of blood clot-related conditions. The presence of this compound as an impurity is significant for quality control and ensuring the safety and efficacy of the final drug product.
Additionally, given the structural complexity and potential for biological activity, (dl)-5-chloro-N-[2-hydroxy-3-[[4-(3-oxo-4-morpholino)phenyl]amino]propyl]-2-thiophenecarboxamide may also be investigated for other pharmaceutical applications, such as the development of new drugs targeting various diseases, based on its ability to interact with specific biological receptors or enzymes. Further research would be required to explore these potential uses.
Check Digit Verification of cas no
The CAS Registry Mumber 482305-98-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,8,2,3,0 and 5 respectively; the second part has 2 digits, 9 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 482305-98:
(8*4)+(7*8)+(6*2)+(5*3)+(4*0)+(3*5)+(2*9)+(1*8)=156
156 % 10 = 6
So 482305-98-6 is a valid CAS Registry Number.
482305-98-6Relevant articles and documents
Rivaroxaban oxazolidine impurity reference substance and preparation method thereof
-
Paragraph 0024-0026; 0030-0032; 0036-0038; 0042-0044; 0048, (2019/02/13)
The invention discloses a rivaroxaban oxazolidine impurity, and the impurity has a structural formula shown in the description. The invention also discloses a preparation method of the oxazolidine impurity, comprising the steps of: hydrolyzing rivaroxaban
N-epoxy propyl-N-acyl aniline compounds, process for their preparation and use
-
Paragraph 0109; 0110; 0111, (2016/10/10)
The present invention discloses a class of N-epoxypropyl-N-acylaniline compounds represented by a formula (I), and further discloses a preparation method of the N-epoxypropyl-N-acylaniline compounds, and applications of the N-epoxypropyl-N-acylaniline compounds in preparation of oxazolidinone treating drugs including but being not limited to linezolid and rivaroxaban racemate or optical isomers, wherein R1 represents morpholinyl or 3-O-4-morpholinyl, R2 represents H or F, R3 represents C1-12 alkyl, thien-2-yl or 5-chlorothiophen-2-yl, and the compounds are racemates, (S)-optical isomers, or (R)-optical isomers.
MICROANGIOPATHY TREATMENT AND PREVENTION
-
, (2010/07/04)
The present invention relates to the use of selective factor Xa inhibitors, in particular of oxazolidinones of the formula (I) for the treatment and/or prophylaxis of microangiopathies and also their use for the production of medicaments for the treatment and/or prophylaxis of microangiopathies.
